Informações:
Falhas:
ID
19596
Descrição
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT00391092
Link
https://clinicaltrials.gov/show/NCT00391092
Palavras-chave
Versões (1)
- 13/01/2017 13/01/2017 -
Transferido a
13 de janeiro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00391092
Eligibility Breast Cancer NCT00391092
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00391092
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adult | Age
Item
adult patients, >=18 years of age;
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
HER2-positive carcinoma of breast | Lesion Recurrent Local | Metastatic Lesion
Item
her2 positive breast cancer with locally recurrent or metastatic lesions;
boolean
C1960398 (UMLS CUI [1])
C0221198 (UMLS CUI [2,1])
C2945760 (UMLS CUI [2,2])
C1513183 (UMLS CUI [3])
C0221198 (UMLS CUI [2,1])
C2945760 (UMLS CUI [2,2])
C1513183 (UMLS CUI [3])
eligible Chemotherapy
Item
eligible for chemotherapy;
boolean
C1548635 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,2])
Left ventricular ejection fraction
Item
baseline lvef >=50%.
boolean
C0428772 (UMLS CUI [1])
Chemotherapy Secondary malignant neoplasm of female breast | Chemotherapy Breast cancer recurrent Local
Item
previous chemotherapy for metastatic or locally recurrent breast cancer;
boolean
C0392920 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0278493 (UMLS CUI [2,2])
C0205276 (UMLS CUI [2,3])
C0346993 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0278493 (UMLS CUI [2,2])
C0205276 (UMLS CUI [2,3])
Therapeutic radiology procedure Secondary malignant neoplasm of female breast | Therapeutic radiology procedure Metastatic bone pain relief
Item
previous radiotherapy for metastatic breast cancer (except for metastatic bone pain relief);
boolean
C1522449 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0877420 (UMLS CUI [2,2])
C0564405 (UMLS CUI [2,3])
C0346993 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0877420 (UMLS CUI [2,2])
C0564405 (UMLS CUI [2,3])
primary tumor | Basal cell carcinoma | Squamous cell carcinoma of skin | Carcinoma in situ of uterine cervix
Item
other primary tumor within last 5 years, with the exception of basal or squamous skin cancer, or in situ cancer of the cervix;
boolean
C0677930 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0553723 (UMLS CUI [3])
C0851140 (UMLS CUI [4])
C0007117 (UMLS CUI [2])
C0553723 (UMLS CUI [3])
C0851140 (UMLS CUI [4])
Cardiovascular Disease Clinical Significance
Item
clinically significant cardiovascular disease;
boolean
C0007222 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C2826293 (UMLS CUI [1,2])
ASPIRIN USE CHRONIC U/day | clopidogrel chronic U/day
Item
chronic daily treatment with aspirin (>325mg/day) or clopidogrel (>75mg/day).
boolean
C0741254 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C0070166 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0456683 (UMLS CUI [1,2])
C0070166 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])